Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014070 (
encephalomyelitis
)
13,017
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The therapeutic effects of mercaptopurine (6-mercaptopurine,
6-MP
) and a silylated derivative (6-trimethylsilylthio-9-trimethyl-silylpurine, S-MP) were compared on the course of T lymphocyte line mediated experimental allergic
encephalomyelitis
(t-EAE). This transferred EAE is a passively induced model disease in Lewis rats easy to elicit, reliably reproducible and characterized by a dose-dependent lethality. If given at different points in single injections the silicon derivative is shown to be more efficient than
6-MP
(43/125 surviving animals compared to 26/129), severity of disease is attenuated and number of survivors increased. Silylation is able to improve blood-brain barrier and cellular permeability; S-MP suppresses intrathecal inflammatory cells more effectively than the original immunosuppressant.
...
PMID:[Mercaptopurine and silylated mercaptopurine the treatment of experimental allergic encephalomyelitis]. 234 4
1.
6-Mercaptopurine
(
6-MP
) prevents experimental allergic
encephalomyelitis
(EAE) during the period of drug administration in both rabbits and guinea pigs. The disease is suppressed even when treatment is started as late as the 5th day after antigenic stimulation in guinea pigs and the 12th day in rabbits. 2. After discontinuation of
6-MP
treatment, there is a latent period before the disease is noted. The length of this latent period is not modified by the duration of
6-MP
treatment. 3. The effect of
6-MP
on EAE is not the result of leukopenia, non-specific toxicity and debilitation, anti-inflammatory activity, or mere masking of clinical signs of the disease. It is, rather, the result of
6-MP
's specific anti-immunologic activity. 4. The effects of
6-MP
on antibody production, delayed hypersensitivity, and EAE are compared. This provides indirect evidence for the importance of circulating antibody in the pathogenesis of EAE. 5. The important considerations in the use of
6-MP
are discussed and the possible usefulness of
6-MP
in human neurologic diseases is considered.
...
PMID:Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine. 1444 35
